These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28626025)

  • 1. Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease.
    Royce SG; Rele S; Broughton BRS; Kelly K; Samuel CS
    FASEB J; 2017 Sep; 31(9):4168-4178. PubMed ID: 28626025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid.
    Royce SG; Mao W; Lim R; Kelly K; Samuel CS
    FASEB J; 2019 May; 33(5):6402-6411. PubMed ID: 30768365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasally administered serelaxin abrogates airway remodelling and attenuates airway hyperresponsiveness in allergic airways disease.
    Royce SG; Lim CX; Patel KP; Wang B; Samuel CS; Tang ML
    Clin Exp Allergy; 2014 Nov; 44(11):1399-408. PubMed ID: 25113628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease.
    Royce SG; Shen M; Patel KP; Huuskes BM; Ricardo SD; Samuel CS
    Stem Cell Res; 2015 Nov; 15(3):495-505. PubMed ID: 26426509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serelaxin improves the therapeutic efficacy of RXFP1-expressing human amnion epithelial cells in experimental allergic airway disease.
    Royce SG; Tominaga AM; Shen M; Patel KP; Huuskes BM; Lim R; Ricardo SD; Samuel CS
    Clin Sci (Lond); 2016 Dec; 130(23):2151-2165. PubMed ID: 27647937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a novel model incorporating airway epithelial damage and related fibrosis to the pathogenesis of asthma.
    Royce SG; Patel KP; Samuel CS
    Lab Invest; 2014 Dec; 94(12):1326-39. PubMed ID: 25264707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressive effect of compact bone-derived mesenchymal stem cells on chronic airway remodeling in murine model of asthma.
    Ogulur I; Gurhan G; Aksoy A; Duruksu G; Inci C; Filinte D; Kombak FE; Karaoz E; Akkoc T
    Int Immunopharmacol; 2014 May; 20(1):101-9. PubMed ID: 24613203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratracheal Administration of Mesenchymal Stem Cells Modulates Tachykinin System, Suppresses Airway Remodeling and Reduces Airway Hyperresponsiveness in an Animal Model.
    Urbanek K; De Angelis A; Spaziano G; Piegari E; Matteis M; Cappetta D; Esposito G; Russo R; Tartaglione G; De Palma R; Rossi F; D'Agostino B
    PLoS One; 2016; 11(7):e0158746. PubMed ID: 27434719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parabromophenacyl bromide inhibits subepithelial fibrosis by reducing TGF-β1 in a chronic mouse model of allergic asthma.
    Ram A; Mabalirajan U; Jaiswal A; Rehman R; Singh VP; Ghosh B
    Int Arch Allergy Immunol; 2015; 167(2):110-8. PubMed ID: 26303861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with relaxin and methylprednisolone augments the effects of either treatment alone in inhibiting subepithelial fibrosis in an experimental model of allergic airways disease.
    Royce SG; Sedjahtera A; Samuel CS; Tang ML
    Clin Sci (Lond); 2013 Jan; 124(1):41-51. PubMed ID: 22817662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trefoil factor-2 reverses airway remodeling changes in allergic airways disease.
    Royce SG; Lim C; Muljadi RC; Samuel CS; Ververis K; Karagiannis TC; Giraud AS; Tang ML
    Am J Respir Cell Mol Biol; 2013 Jan; 48(1):135-44. PubMed ID: 22652198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of roflumilast on airway remodelling in a murine model of chronic asthma.
    Kim SW; Kim JH; Park CK; Kim TJ; Lee SY; Kim YK; Kwon SS; Rhee CK; Yoon HK
    Clin Exp Allergy; 2016 May; 46(5):754-63. PubMed ID: 26542330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human pluripotent stem cell-derived mesenchymal stem cells prevent chronic allergic airway inflammation via TGF-β1-Smad2/Smad3 signaling pathway in mice.
    Zhong H; Fan XL; Fang SB; Lin YD; Wen W; Fu QL
    Mol Immunol; 2019 May; 109():51-57. PubMed ID: 30852246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD11b+ and Sca-1+ Cells Exert the Main Beneficial Effects of Systemically Administered Bone Marrow-Derived Mononuclear Cells in a Murine Model of Mixed Th2/Th17 Allergic Airway Inflammation.
    Cruz FF; Borg ZD; Goodwin M; Coffey AL; Wagner DE; Rocco PR; Weiss DJ
    Stem Cells Transl Med; 2016 Apr; 5(4):488-99. PubMed ID: 26933041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for allergic airways disease.
    Patel KP; Giraud AS; Samuel CS; Royce SG
    Br J Pharmacol; 2016 Jun; 173(12):2016-29. PubMed ID: 27060978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease.
    Alcorn JF; Rinaldi LM; Jaffe EF; van Loon M; Bates JH; Janssen-Heininger YM; Irvin CG
    Am J Respir Crit Care Med; 2007 Nov; 176(10):974-82. PubMed ID: 17761617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of airway remodeling in acute, subacute, and chronic models of allergic airways disease.
    Locke NR; Royce SG; Wainewright JS; Samuel CS; Tang ML
    Am J Respir Cell Mol Biol; 2007 May; 36(5):625-32. PubMed ID: 17237192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma.
    Rhee CK; Lee SY; Kang JY; Kim SJ; Kwon SS; Kim YK; Park SH
    Int Arch Allergy Immunol; 2009; 148(4):289-96. PubMed ID: 19001788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary myeloid cell uptake of biodegradable nanoparticles conjugated with an anti-fibrotic agent provides a novel strategy for treating chronic allergic airways disease.
    Chakraborty A; Pinar AA; Lam M; Bourke JE; Royce SG; Selomulya C; Samuel CS
    Biomaterials; 2021 Jun; 273():120796. PubMed ID: 33894403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
    Muz MH; Deveci F; Bulut Y; Ilhan N; Yekeler H; Turgut T
    Exp Mol Med; 2006 Apr; 38(2):109-18. PubMed ID: 16672764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.